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Neuroligin-1 is altered in the 
hippocampus of Alzheimer’s 
disease patients and mouse 
models, and modulates the toxicity 
of amyloid-beta oligomers
Julien Dufort-Gervais1,2, Chloé Provost2, Laurence Charbonneau3, Christopher M. Norris4, 
Frédéric calon5,6, Valérie Mongrain  2,3,7 ✉ & Jonathan Brouillette1,2,7 ✉
Synapse loss occurs early and correlates with cognitive decline in Alzheimer’s disease (AD). 
Synaptotoxicity is driven, at least in part, by amyloid-beta oligomers (Aβo), but the exact synaptic 
components targeted by Aβo remain to be identified. We here tested the hypotheses that the 
post-synaptic protein Neuroligin-1 (NLGN1) is affected early in the process of neurodegeneration 
in the hippocampus, and specifically by Aβo, and that it can modulate Aβo toxicity. We found 
that hippocampal NLGN1 was decreased in patients with AD in comparison to patients with mild 
cognitive impairment and control subjects. Female 3xTg-AD mice also showed a decreased NLGN1 
level in the hippocampus at an early age (i.e., 4 months). We observed that chronic hippocampal 
Aβo injections initially increased the expression of one specific Nlgn1 transcript, which was followed 
by a clear decrease. Lastly, the absence of NLGN1 decreased neuronal counts in the dentate gyrus, 
which was not the case in wild-type animals, and worsens impairment in spatial learning following 
chronic hippocampal Aβo injections. Our findings support that NLGN1 is impacted early during 
neurodegenerative processes, and that Aβo contributes to this effect. Moreover, our results suggest 
that the presence of NLGN1 favors the cognitive prognosis during Aβo-driven neurodegeneration.
Synapse loss is an early event in the pathogenesis of Alzheimer’s disease (AD) and correlates with cognitive 
decline of the patients1–3. Hippocampus-dependent memory for recent facts and events (explicit memory) is 
among the first type of memory that is affected in the disease because of the neurodegenerative process that rap-
idly and gradually takes place in the hippocampus at the onset of AD4,5. More precisely, within the hippocampal 
network, the perforant path that connects the entorhinal cortex to the dentate gyrus (DG) is one of the earliest 
and most severely affected pathways in AD6,7. This suggests that the DG is among sites showing initial signs of 
synaptic dysfunction, including in glutamatergic transmission8, and that it could represent an area of particular 
relevance for early interventions.
Despite decades of research focused on the amyloid-beta (Aβ) peptide, its causal role in AD pathogenesis 
remains unclear at the molecular level. However, strong evidence suggests that soluble Aβ oligomers (Aβo) are 
particularly neurotoxic and that their presence can correlate with memory deficits in AD patients and animal 
models, especially when considering oligomers derived from Aβ1-42 peptides9–18. Soluble Aβo start to accumu-
late in the human brain ~10 to 15 years before clinical symptoms and were shown to induce losses of excitatory 
synapses and neurons19–22. The oligomerization of Aβ is rapid and it has been suggested that Aβ toxicity results 
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from multiple small Aβ species present at the same time, rather than from one particular type of soluble oli-
gomer11,18,23,24. Although the toxicity (including synaptotoxicity) of soluble Aβo is well established, specific synap-
tic components that are altered when Aβo begin to increase in the brain at the onset of AD remain to be identified. 
Identifying Aβo-driven changes in proteins specifically involved in excitatory synapse functioning is required 
to understand glutamatergic synapse dysfunction and loss, which likely takes place before neurodegeneration 
induces substantial and irreversible brain damage permanently affecting cognition and autonomy.
Neuroligins (NLGNs) are post-synaptic adhesion proteins that interact with pre-synaptic protein neurex-
ins (NRXNs) and have roles in synapse formation, maturation, maintenance and plasticity25–27. Neuroligin-1 
(NLGN1) predominantly localizes at excitatory post-synaptic densities28, and previous work has linked it to neu-
ropsychiatric and neurological disorders such as autism, schizophrenia and stroke29–31. Interestingly, NLGN1 has 
also been shown to be involved in synaptic plasticity, N-methyl-D-aspartate (NMDA) receptor function, memory 
and sleep regulation25,32,33, which are all altered in AD. The relevance of NLGN1 (and NRXNs) in the context of 
AD neurodegeneration has been emphasized in the last decade3,34,35. In fact, a single dose of Aβ1-40 fibrils has been 
shown to negatively impact NLGN1 in rats, which impaired synaptic function and memory36. In addition, Aβo 
were shown to bind to NLGN1 in vitro, and interfering with this interaction was observed to modulate synaptic 
integrity37,38. Moreover, NLGN1 was recently shown to be decreased in the plasma of patients with AD as well 
as in the preclinical period39. Nonetheless, to the best of our knowledge, it remains to be determined whether 
NLGN1 is altered in the hippocampus of AD patients as well as whether it is involved in the specific hippocampal 
pathology induced in vivo by soluble low-molecular-weight Aβo1-42.
Therefore, we here aimed to fill this knowledge gap using quantifications of the NLGN1 level in the hip-
pocampus of patients with AD as well as in two animal models with Aβ-driven neurodegeneration. Importantly, 
we assessed the time course of the effect on NLGN1 by performing quantifications also in patients with amnesic 
mild cognitive impairment (aMCI), in triple transgenic (3xTg-AD) mice of 4, 12 and 18 months, and in mice 
submitted to 2, 4 and 6 days of Aβo1-42 injection in the hippocampus. In addition, we tested whether the absence 
of NLGN1 aggravates memory impairment and neuronal losses caused by Aβo1-42 using chronic hippocampal 
Aβo1-42 injections combined to immunohistochemistry and assessments of spatial and working memory. We 
found that the level of NLGN1 is decreased in the hippocampus of aMCI and AD patients and in young 3xTg-AD 
female mice, and that hippocampal Aβo1-42 injections decreased neuronal count in the DG and induced spatial 
learning deficits predominantly in Nlgn1 knockout (KO) mice. Our results provide support to the hypothesis 
that NLGN1 is impacted early during Aβ pathology and that it modulates cognitive functions during Aβo-driven 
neurodegeneration.
Methods
Human brain tissues. Hippocampal protein samples from individuals with aMCI, AD patients and age-
matched non-demented control subjects (CTRL) were provided by the brain bank of the Alzheimer’s Disease 
Center of the University of Kentucky40. AD and aMCI were diagnosed using clinical evaluations as previously 
described40. Briefly, cognitive status, neurologic and physical examinations were performed annually or bian-
nually with a follow up of at least 2 years before death. All subjects had no comorbidity with substance abuse, 
head injury, encephalitis, meningitis, epilepsy, stroke, infectious disease or major psychiatric illness. Mini-mental 
state examination (MMSE) score was used as an indicator of overall cognitive status41, with a lower score being 
indicative of deficits in memory, attention, orientation and/or language. MMSE score was on average 24.4 and 
7.8 in aMCI and AD patients, respectively (Table 1). Cognitive state was also evaluated with the animal naming 
test (ANIMALS: number of animals named in 1 min, with 12 generally considered as the cutoff for impairment), 
the Boston naming test (BNT: 15-item version with lower score indicating deficits), and the controlled oral word 
association test (COWA: sum of three trials of verbal fluency, lower score indicating impairment; Table 1). CTRL 
subjects were at Braak stage 0 or 1 and scored on average 27.8 on the MMSE (Table 1). Subjects were selected 
based on the shortest post-mortem interval (PMI) available to avoid protein degradation (Table 1). Other char-
acteristics of patients and subjects are also listed in Table 1. Protocols for subjects and patients examinations and 
for the use of postmortem human brain tissue were approved by the University of Kentucky Institutional Review 
Board, and informed consent was obtained from all participants. All methods were performed in accordance with 
relevant guidelines and regulations.
Animals. Male and female 3xTg-AD (APPswe, PS1M146V, tauP301L) mice42, and control non-transgenic 
mice of the same genetic background (i.e., C57BL/6-129/SvJ) were produced and maintained at the animal 
facility of the Research Center of the Centre Hospitalier de l’Université Laval as previously described43. Male 
C57BL/6 J, Nlgn1 KO mice and wild-type (WT) littermates were used for chronic Aβo1-42 injections. C57BL/6 J 
mice (n = 41) were purchased from Jackson Laboratories and submitted to cannula implantation surgery at 13 
weeks (see below). Mice heterozygous for the Nlgn1 mutation (B6;129-Nlgn1tm1Bros/J44) were purchased from 
Jackson Laboratories, backcrossed with C57BL/6 J mice for >10 generations, and bred at the animal facility of 
the Research Center of the Hôpital du Sacré-Coeur de Montréal. KO and WT mice were implanted with cannulas 
for intra-hippocampal Aβo injections at 24 ± 10 weeks. Animals were housed individually and maintained in 
a 12 h light/12 h dark cycle at a temperature of 24 ± 1 °C with food and water available ad libitum. The experi-
ment involving 3xTg-AD mice was approved by the Animal Welfare Committee of the Université Laval accord-
ing to guidelines of the Canadian Council on Animal Care. All other experimental procedures were approved 
by the Comité d’éthique de l’expérimentation animale of the Hôpital du Sacré-Coeur de Montréal (Recherche 
CIUSSS-NIM) also in accordance with guidelines of the Canadian Council on Animal Care.
Aβo1-42 preparation and Aβ quantification. Preparation of the Aβo1-42 and control Aβ1-42 scrambled 
(AβScr) solutions were performed as previously described12. Briefly, synthetic Aβ1-42 and AβScr (rPeptide, Cat 
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No. A-1163-2 and A-1004-1, respectively) were suspended in hexafluoroisopropanol (HFIP) (Acros Organics, 
Cat No. 147541000). The HFIP was evaporated with nitrogen gas and Aβ1-42 peptides were resuspended in DMSO 
(Sigma-Aldrich, Cat No. D-4540). The solution was eluted through a HiTrap desalting column (GE Healthcare, 
Cat No. 17-1408-01) previously equilibrated with a Tris-EDTA solution (50 mM Tris, 1 mM EDTA). Aβ1-42 pep-
tides were quantified using the BCA protein assay kit (Thermo Fisher, Cat No. 23225) and stored at −80 °C. The 
average concentration of the solutions used in this study was 0.28 ± 0.04 μg/μL. The biophysical and biological 
properties as well as the level of oligomerization of this Aβ preparation have been previously characterized12,45,46. 
The Aβ solution was kept at room temperature for 1 h before injection to induce oligomerization and produce 
soluble low-molecular-weight Aβo1-42 as previously done12. Soluble Aβ quantification in post-mortem tissue was 
performed by a standard three-step serial extraction procedure as described elsewhere for these samples40. The 
Aβ quantification was not available for 4 CTRL, 6 aMCI and 4 AD patients (Table 1).
Surgical procedure and injections. The cannula implantation surgery was adapted from the procedure 
previously described12,47. Briefly, mice were anesthetized with Ketamine/Xylazine (120/10 mg/kg), installed on a 
stereotaxic apparatus and maintained under anesthesia using 1% isoflurane. Stereotaxic coordinates of the two 
cannulas implanted just above the DG were defined as 2.3 mm posterior to the bregma, ±1.5 mm from midline 
and 1.8 mm below the skull surface. Three screws were inserted into the skull to stabilize cannulas fixed to the 
skull with dental cement. Mice were given buprenorphine (0.1 mg/kg) immediately after the surgery and the day 
after to ensure sufficient analgesia.
The injections were conducted as previously described12,47. In brief, one week after recovery, freely moving 
mice were injected with Aβ solutions or an equal volume of control AβScr or vehicle (VH: 50 mm Tris, 1 mm 
EDTA, pH 7.5) at a constant rate of 0.2 μl/min via cannulas and PE50 tubing (Plastics One) connected to a 
Hamilton syringe pump system (KD Scientific, KDS310). The tubing was left in place for 5 min after each injec-
tion and cannulas were capped after tubing removal to prevent reflux of the injected solution. Injections were 
performed during the first half of the light phase and were repeated for 2, 4 or 6 consecutive days.
Protein extraction and Western blot. Proteins extracted from human hippocampi represented the mem-
brane fraction as detailed elsewhere38. For mouse experiments, hippocampal tissues were homogenized in cold 
RIPA buffer 1X (Thermo Fisher, Cat No. 89901) with 0.5% CHAPS (Fisher BioReagents, Cat No. BP571-1) and 
phosphatase and protease inhibitors (Thermo scientific, Cat No. A32961). Samples were sonicated, gently agi-
tated at 4 °C for 1 h, and centrifuged at 14000 g for 20 min at 4 °C. The supernatant containing total proteins 
was collected and the protein concentration was quantified using the Pierce BCA protein assay kit. Thirty μg of 
proteins per sample were separated by electrophoresis using Bolt 4-12% Bis-Tris gels (Thermo Fisher, Cat No. 
NW04122BOX) and transferred onto a PVDF membrane (Immobilon-Psq, Cat No. ISEQ00010). Membranes 
were incubated 1 h with Odyssey blocking buffer (Type PBS) (LiCor, Cat No. 927-40000) at room temperature 
and incubated overnight at 4 °C with anti-NLGN1 antibodies (Millipore, Cat No. MABN742, used at 1:1000 for 
human samples; Synaptic Systems, Cat No. 129 111, used at 1:1000 for all non-human samples), anti-PSD95 
antibodies (Millipore, Cat No. 04-1066, 1:1500), or anti-GAPDH antibodies (Cell Signaling Technology, Cat No. 
5174, 1:1000) diluted in Odyssey blocking buffer (Type PBS) containing 0.2% Tween 20 (Fisher BioReagents, 
Cat No. BP337-500). Membranes were then washed and incubated with corresponding secondary antibodies 
(LiCor, IRDye 800CW, 1:15000; IRDye 680RD, 1:15000; Cell Signaling Technology, HRP linked antibody No. 
7076, 1:1000) diluted in Odyssey blocking buffer (Type PBS) containing 0.2% Tween 20 and 0.01% SDS for 1 h at 
room temperature. Membranes were revealed using the Odyssey CLx (LiCor, Cat No. 9140) with Image Studio 
3.1 software. For some blots, chemiluminescence was visualized using an ECL detection kit (Thermo Scientific, 
Cat No. 1859022). Quantitative densitometric analysis was performed using ImageJ and expressed relative to 
Characteristics Units CTRL aMCI AD
Age years 86.9 ± 1.7 89.5 ± 1.6 86.1 ± 1.2
Sexe
♀ (n) 7 5 6
♂ (n) 5 6 7
PMI hours 3.1 ± 0.1 3.7 ± 0.7 3.3 ± 0.2
NFTs #/mm2 2.5 ± 1.4a 12.2 ± 4.0 33.3 ± 6.9a
Hippocampal soluble 
Aβ ρmol/g 522.0 ± 135.1
b 2006.8 ± 733.4c 5763.9 ± 1364.3d
MMSE score 27.8 ± 0.7 24.4 ± 1.0 7.8 ± 2.3a
ANIMALS score 13.1 ± 1.5 13.7 ± 1.7e 11.4 ± 2.2f
BNT score 14.1 ± 0.3 13.9 ± 0.4e 12.3 ± 1.4g
COWA score 38.3 ± 3.7 35.0 ± 4.1d 28.7 ± 5.7f
Table 1. Characteristics of humans from which brain samples were collected. CTRL: control subjects; aMCI: 
amnesic mild cognitive impairment subjects; AD: Alzheimer’s disease patients; PMI: post-mortem interval; 
NFTs: neurofibrillary tangles; Aβ: amyloid-beta; MMSE: mini-mental state examination; ANIMALS: animal 
naming test; BNT: Boston naming test; COWA: controlled oral word association test. Some aMCI and AD 
patients could not complete some cognitive tests. an = 11; bn = 8, cn = 5; dn = 9; en = 10; fn = 7; gn = 6.
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GAPDH. At least one control sample was loaded on each blot as a calibrator for quantification. Full length blots 
are presented in Supplementary Information.
mRNA extraction and qPCR. mRNA extraction, reverse transcription and qPCR procedures were per-
formed as previously described48–50. Briefly, hippocampal mRNA was extracted using the RNeasy Lipid Tissue 
mini kit according to manufacturer’s instructions (Qiagen, Cat No. 74804). Reverse transcription was performed 
with SuperScript II Reverse transcriptase (Invitrogen, Cat No. 18064014) following the manufacturer’s instruc-
tions including 10 min at 25 °C and 60 min at 42 °C. QPCR was performed using 384-well plates with a mix of 
RNAase free water, TaqMan Fast Advanced Master Mix (Applied Biosystems, Cat No. 4444557), and primers and 
probes for each gene (Table 2). Given that NLGN1 has isoforms with different properties51, five different probe 
sets were used to quantify Nlgn1 expression as previously performed48–50. Nlgn1A corresponds to the sequence 
containing insert A and Nlgn1B with insert B, while Nlgn1NA is a sequence without insert A and Nlgn1NB with-
out insert B. N1gn1C corresponds to a common sequence targeting transcripts with only insert A, only insert 
B, both inserts and no insert. The expression of four additional genes coding for related synaptic proteins have 
also been quantified (Nlgn2, Nrxn1, Nrxn2, Nrxn3). Three endogenous control genes (GusB, Rps9 and Tbp) were 
quantified to normalize expression level of Nlgn1 variants and of related mRNA. Gene expression was measured 
using a Viia 7 thermal cycler (Thermo Fisher) with the following cycling conditions: 2 min at 50 °C, 20 sec at 95 °C, 
40 times 1 sec at 95 °C and 20 sec at 60 °C. The analysis was performed with Expression Suite (Life Technologies), 
which calculated gene expression relative to endogenous controls and to one sample of the control group (mod-
ified delta delta Ct).
Primary hippocampal culture and cell viability. The primary neuronal culture procedure was car-
ried out as described previously12. Briefly, pregnant Long-Evans female rats were ordered from Charles River 
Laboratories and sacrificed at embryonic day 18. Hippocampi were dissected, transferred to a tube containing 
HBSS (Sigma-Aldrich, Cat No. H1641), HEPES (Gibco, Cat No. 15630-080), penicillin/streptomycin/ampho-
tericin (Gibco, Cat No. 15240-062) and 3 mM sodium pyruvate (Gibco, Cat No. 25080-094) at 37 °C, and were 
Gene Type Manufacturer Sequence (5′ to 3′) or Taqman Gene Expression Assay number
GusB
Forward Operon ACGGGATTGTGGTCATCGA
Reverse Operon TGACTCGTTGCCAAAACTCTGA
Probe Operon [6-FAM]-AGTGTCCCGGTGTGGGCATTGTG-[TAMRA]
Nlgn1A
Forward Microsynth ACGGTGCTGAAGATGAAG
Reverse Microsynth CAGTACCTTCCATGTAAGAG
Probe Eurogentec [6-FAM]-TCCCAAACCAGTGATGGTGTACATCCA-[BHQ1]
Nlgn1NA
Forward Microsynth GGATGTGGTTTCATCATAC
Reverse Microsynth TGTCCCGAATATCATCTTC
Probe Eurogentec [6-FAM]-TCCAAGACCAGAGTGAAGACTGTC-[BHQ1]
Nlgn1B
Forward Microsynth GGTAACCGTTGGAGCAATTCA
Reverse Microsynth CCAGCTGGAAAGGGCTGTT
Probe Eurogentec [6-FAM]-CCAAAGGACTTTTTCAACGAGCAATAGCTCA-[BHQ1]
Nlgn1NB
Forward Microsynth CACTGTGTTTGGATCAGG
Reverse Microsynth AAAAGTCCTTCAGAATAATGGG
Probe Eurogentec [6-FAM]-GGTTCATGTGTCAACCTGCTGACT-[BHQ1]
Nlgn1C
Forward Microsynth TCCTTGCAATTTCTCCAAGA
Reverse Microsynth TTGGGTTTGGTATGGATGAA
Probe Eurogentec [6-FAM]-TGGTGACCCAAATCAACCAGTTCC-[BHQ1]
Nlgn2 Probe set Thermo Sci. Mm01703404_m1
Nrxn1 Probe set Thermo Sci. Mm00660298_m1
Nrxn2 Probe set Thermo Sci. Mm01236851_m1
Nrxn3 Probe set Thermo Sci. Mm04279482_m1
Rps9
Forward Operon GACCAGGAGCTAAAGTTGATTGGA
Reverse Operon TCTTGGCCAGGGTAAACTTGA
Probe Operon [6-FAM]-AAACCTCACGTTTGTTCCGGAGTCCATECT-[TAMRA]
Tbp
Forward Operon TTGACCTAAAGACCATTGCACTTC
Reverse Operon TTCTCATGATGACTGCAGCAAA
Probe Operon [6-FAM]-TGCAAGAAATGCTGAATATAATCCCAAGCG-[TAMRA]
Table 2. List of probes and primers used for qPCR. BHQ1: Black Hole Quencher-1 GusB: beta-glucuronidase 
B; Nlgn1A: neuroligin-1 with insert in splice site A; Nlgn1NA: neuroligin-1 without insert in splice site A; 
Nlgn1B: neuroligin-1 with insert in splice site B; Nlgn1NB: neuroligin-1 without insert in splice site B; Nlgn1C: 
neuroligin-1 common to all transcript variants; Nlgn2: neuroligin-2; Nrxn1: neurexin-1; Nrxn2: neurexin-2; 
Nrxn3: neurexin-3; Rps9: ribosomal protein S9; Tbp: TATA-box binding protein; FAM: 6-carboxyfluorescein; 
TAMRA: tetramethylrhodamine.
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treated with 0.25% trypsin (Life Technologies, Cat No. 15090-046), agitated at 900 rpm for 15 min at 37 °C, 
and dissociated by trituration. Cells were platted in 12-well plates (Costar, Cat No. 3513) coated with poly-D 
lysine hydrobromide (Sigma-Aldrich, Cat No. P6407- 5MG) and containing minimum essential medium 
(Sigma-Aldrich, Cat No. M0275) supplemented with 10% horse serum (Sigma-Aldrich, Cat No. H1138), 3 mM 
sodium pyruvate, 25 mM D-Glucose (Sigma, Cat BP-250), 2 mM GlutaMax (Sigma, Cat No. RNBD9302), and 
1% penicillin/streptomycin/amphotericin. Plates were incubated at 37 °C with 5% CO2 overnight, and the initial 
culture medium was replaced the day after with Neurobasal medium (Gibco, Cat No. 21103-049) supplemented 
with 2% B27 (Gibco, Cat No. 17504-044), 2 mM GlutaMax, and 0.5% penicillin/streptomycin/amphotericin. 
Primary hippocampal cells were cultured for 7 days before starting treatments. For Western blot analysis, cells 
were washed with cold 10 mM PBS, scratched off the wells with 140 uL of cold RIPA 1X buffer containing CHAPS 
and phosphatase and protease inhibitors, and rapidly stored at −80 °C. Protein extraction and Western blotting 
were performed as described above.
Cell viability was measured using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, 
Cat No. G358B) according to the manufacturer’s protocol. Briefly, the CellTiter 96 AQueous One Solution rea-
gent was added to the Neurobasal medium containing the cells (v/v ratio of 1:5) and after 1.5 h of incubation at 
37 °C the absorbance was recorded at 490 nm. The tested conditions were normalized to values obtained with 
water-treated wells.
Spatial object recognition (SOR) test. The SOR task was conducted 24 hours after the last hippocam-
pal injection (Supplementary Fig. 1) in Nlgn1 KO mice and wild-type (WT) littermates similar to previously 
described52. It was done in an opaque plastic arena (45 × 45 cm) with the floor covered with litter that was mixed 
after each trial to eliminate olfactory cues. The four walls contained different visual cues and two different objects 
were placed in adjacent corners of the arena. The walls and objects were cleaned with 70% ethanol between each 
mouse. During the first day, mice explored the arena and objects for 5 min. Twenty-four hours later, one of the 
two objects was moved to the opposite corner of the arena and mice were reintroduced in the arena for 5 min. The 
number of interactions with each object, defined as a touch of the snout or sniffing of the object by the mouse, was 
counted by an experimenter blind to the genotype and treatment. The discrimination index (DI) was calculated 
for the number of interactions according to the following formula: (moved object - fixed object)/(moved object 
+ fixed object).
Y-maze test. A two-trial Y-maze task was performed 48 hours after the SOR test (Supplementary Fig. 1) as 
previously described12. The three arms of the Y maze were 39 cm long, 15 cm wide and 40.5 cm high. The floor of 
the maze was covered with litter and different visual cues were placed at the top of the end of each arm. During 
the first trial, mice were placed at the end of one arm and were allowed to explore the two arms of the maze freely 
during 5 min without access to the third arm. The blocked arm was alternated between each mouse. Mice were 
returned to their home cage for 5 min and then reintroduced into the same starting arm of the Y-maze to explore 
all three accessible arms for 2 min. Movements of the mouse were analyzed using the Smart acquisition software 
(Harvard Apparatus) to extract time spent in the new arm and the average time spent in the other two arms. The 
walls were cleaned with 70% ethanol and the litter was mixed between each mouse to avoid olfactory cues.
Morris water maze (MWM) test. The MWM task was conducted 48 hours after the Y-maze test 
(Supplementary Fig. 1) as previously described53. Mice were trained in a 120-cm diameter pool filled with water 
rendered opaque by adding non-toxic white paint. The temperature of the water was kept at 24 ± 1 °C during 
testing. During the first 4 days, mice had to learn to find a submerged platform in the pool using visuo-spatial 
cues installed around the pool. Mice had 3 trials per day with 30 min between each trial. If the mouse failed to 
reach the platform within 60 sec, it was guided to the platform and had to remain on the platform for 10 sec before 
being removed from the pool. The time and distance to reach the platform were extracted by the Smart software 
(Harvard Apparatus). Starting location of the mice was different for each trial. During the probe trial on the fifth 
day, the platform was removed and mice had 60 sec to explore the pool. The time spent in the target quadrant that 
previously contained the platform and in the other quadrants, as well as the number of times the mouse crossed 
the area around the platform (2x the diameter of the platform) were calculated with the Smart software. A final 
cued task of 3 trials was also performed to verify visual acuity and motivation to escape from water. During this 
test, mice had a maximum of 30 sec to reach a visible platform that was moved in a different quadrant between 
each trial. Data were acquired in real time with the Smart software.
Immunofluorescence (IF) staining. Neurons were marked with the NeuN antibody for neuronal count-
ing purpose54, as described below. Staining also served to validate the adequate positioning of cannulas. Brains 
were cut with a HM525NX cryostat (Thermo Scientific, Cat No. 956640) at −20 °C and 10 μm coronal slices were 
mounted on SuperFrost Plus slides (Fisher Scientific, Cat No. 12-550-15). Hippocampal sections were performed 
at ±100 μm from the middle of the injection site. Brain slices were mounted in series on 6 slides, with 4 slices per 
slide. Slides were fixed for 15 min in 10% formalin (Sigma-Aldrich, Cat No. HT501128) and washed with PBS 
(Cell Signaling Technology, Cat No. 9808S). Sections were immersed in a blocking solution (1X PBS, 5% goat 
serum (Cell Signaling Technology, Cat No. 5425), 0.3% Triton X-100 (Fisher BioReagents, Cat No. BP151-500) for 
60 min at room temperature and incubated overnight at 4 °C with anti-NeuN antibodies (Cell Signaling, Cat No. 
24307; 1:1000) diluted in PBS 1X, 1% BSA (Fisher BioReagents, Cat No. BP1600-100) and 0.3% Triton X-100. The 
slides were washed, and incubated with a secondary antibody (Alexa fluor 488, Cell Signaling Technology, Cat. 
No. 4340, 1:1000) for 90 min at room temperature and protected from light. Slides were then washed, dried and 
one drop of Prolong Gold Antifade DAPI (Cell Signaling Technology, Cat No. 8961S) was applied on each section 
before being covered with a coverslip (Thermo Scientific, Cat No. 102455).
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Microscopy. A Zeiss AxioImager 2 fluorescence microscope, a monochrome camera, and the 
StereoInvestigator software (MBF Biosciences) were used to acquire IF images. Wavelength filters of 488 nm and 
350 nm were used to excite the fluorochromes of the secondary antibody and of DAPI. Neuronal counting was 
performed using the Neurolucida Software (MBF Biosciences). The 20X objective was used to precisely identify 
the depth of the injection site. Two mice were excluded from neuronal count and memory assessments because 
the cannula was positioned outside the target region. Using the 40X objective, a 500 μm wide area was defined 
in the DG under the injection site as well as in CA2-CA3 distant to the injection site. Since there was little or 
no cell overlay using 10 μm sections and that NeuN labeling was well defined, the function Detect Cells of the 
Neurolucida program could discriminate between individual cells. This function made it possible to make a 
reliable cell count in the area under the injection site and the distant area, which has been validated by manual 
counting by a blind experimenter. Three to four sections per slide were counted; the average of these sections was 
calculated and analyzed according to genotype and treatment.
Statistical analyses. Statistical analyses of multiple samples were performed using appropriate analyses of 
variance (ANOVAs). One-way ANOVA was used for human sample analysis; two-way ANOVAs were used to 
analyze results of 3xTg-AD mice, cell culture, chronic injections, IF, and most variables of the SOR and MWM 
tests; three-way ANOVA was used for the MWM training phase. Significant effects were decomposed, when 
appropriate, using planned comparisons. Student t tests were used for some analyses of the SOR and the Y-maze. 
Pearson’s correlations were performed to quantify the association between soluble Aβ, MMSE and NLGN1 level. 
The sizes of the different samples were determined on the basis of previous studies in the field. Statistical analyses 
were performed using GraphPad Prism 6.0 and/or JMP 14. Significance threshold was set at 0.05 and the levels of 
statistical significance are identified with *p < 0.05, **p < 0.01, ***p < 0.001. Data are reported as mean ± SEM. 
The number of samples used for each experiment is reported in figure legends.
Results
Lower NLGN1 in AD patients. We first assessed whether the hippocampal level of NLGN1 is decreased 
in AD patients and in individuals with aMCI, a prodromal stage of AD55,56. We found that aMCI individuals 
have lower levels of NLGN1 in the hippocampus compared to age-matched CTRL without cognitive impair-
ment (p < 0.001; Fig. 1A, Supplementary Fig. 2A). Also, NLGN1 level was found to be significantly lower in AD 
Figure 1. NLGN1 hippocampal level is decreased in aMCI individuals and AD patients. (A) NLGN1 level was 
measured in aMCI individuals (n = 11), AD patients (n = 13), and control aged non-demented subjects (CTRL, 
n = 12) by Western blot (left side) and quantified (right side) using GAPDH protein as a loading control. 
Significant differences are represented between indicated groups (one-way ANOVA F2,33 = 23.3; p < 0.0001; 
stars indicating planned comparisons). Full length blots are shown in Supplementary Fig. 2. (B) Pearson 
correlation between soluble Aβ and NLGN1 level showed a significant negative correlation in aMCI individuals 
(n = 5) and AD patients (n = 9) but not in CTRL (n = 8). (C) Pearson correlation between MMSE score and 
NLGN1 level showed a significant positive correlation in aMCI individuals (n = 11) and AD patients (n = 11) 
but not in CTRL (n = 12).
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patients when compared to both aMCI individuals (p < 0.05) and CTRL (p < 0.001). These results suggest that 
there is a decline in human hippocampal NLGN1 level that is matching disease progression. In addition, when 
expressed relative to the synaptic marker PSD95, NLGN1 was significantly decreased in both aMCI and AD in 
comparison to CTRL (p < 0.05; Supplementary Fig. 2B,C), which indicates that the NLGN1 decrease is larger 
than that of PSD95 previously reported to occur early during the neurodegenerative process53. Moreover, we 
found that, in aMCI individuals and AD patients, lower hippocampal level of NLGN1 significantly correlates with 
higher hippocampal level of soluble Aβ (p < 0.01; Fig. 1B) as well as with poorer cognitive state assessed with the 
MMSE (p < 0.01; Fig. 1C).
Lower NLGN1 level in young 3xTg-AD female mice. To further evaluate the fate of NLGN1 in the 
course of neurodegeneration, we measured NLGN1 hippocampal levels in 3xTg-AD male and female mice at 
three different ages (4, 12 and 18 months). This commonly used AD model shows beta-amyloid plaques and 
neurofibrillary tangles with intracellular Aβ accumulation in the hippocampus at 4 months that correlates with 
Figure 2. Age-dependent changes in NLGN1 protein in 3xTg-AD mice. (A) Hippocampal NLGN1 protein 
level measured by Western blot (top) in female 3xTg-AD and control mice at 4, 12 and 18 months, and analyzed 
using GAPDH protein as a control (bottom). A significant Genotype-by-Age interaction was found (two-
way ANOVA F2,33 = 3.8, p = 0.03) showing that NLGN1 protein level differed between 3xTg-AD and control 
mice only at 4 months (stars indicating planned comparison). Full length blots are shown in Supplementary 
Fig. 3 (also in B). (B) Hippocampal NLGN1 protein level measured by Western blot in male 3xTg-AD and 
control mice at 4, 12 and 18 months (top), and analyzed using GAPDH as a control (bottom). No significant 
effect of Genotype was found (two-way ANOVA Genotype main effect: F1,35 = 3.9, p = 0.06; Genotype-by-
Age interaction: F2,35 = 0.12, p = 0.9), but a significant effect of age was observed (Age main effect: F2,35 = 4.4 
p = 0.02). The number of mice is indicated on each bar.
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cognitive deficits42,57. Female 3xTg-AD mice showed considerably lower NLGN1 level at 4 months in comparison 
to control female (p < 0.001; Fig. 2A, Supplementary Fig. 3). NLGN1 level did not significantly differ between 
female 3xTg-AD and control mice at 12 and 18 months. In male mice, NLGN1 hippocampal level did not sig-
nificantly differ between 3xTg-AD and controls at all ages studied (Fig. 2B, Supplementary Fig. 3). Interestingly, 
NLGN1 level decreased with age in males, with a significant difference specifically observed between 4 and 18 
months (p = 0.01). In summary, these data indicate that NLGN1 is rapidly decreased in 3xTg-AD mice, and that 
this decrease is specific to female mice.
NLGN1 level is decreased by Aβo1-42 exposure in vitro. Given our observation that NLGN1 level sig-
nificantly correlates with soluble Aβ in the human hippocampus (Fig. 1B), we next verified whether Aβo1-42 
could directly impact NLGN1 level in vitro, and whether this is linked to neuronal survival. NLGN1 protein 
level and cell viability were measured in primary culture of hippocampal neurons treated with 2 μM of Aβo1-42 
for 48 or 72 hours. As expected from our previous study12, Aβo1-42 significantly decreased neuronal viability by 
about 40% after 72 hours of treatment (p < 0.001; Fig. 3A). No change in viability was observed after 48 hours of 
treatment. NLGN1 protein level was also decreased after 72 hours of Aβo1-42 exposure (p < 0.02) and unchanged 
after 48 hours (Fig. 3B, Supplementary Fig. 4). These data indicate that Aβo1-42 exposure is detrimental to NLGN1 
protein level in hippocampal neurons, which follows a time course similar to neuronal viability.
Nlgn1 mRNA is affected by hippocampal Aβo1-42 injections. We next aimed at identifying the spe-
cific impact of Aβo1-42 on NLGN1 in vivo using chronic (2, 4 or 6 days) hippocampal injections in WT mice. 
In addition, we assessed whether Aβo1-42 affect Nlgn1 in a transcript variant-dependent manner, which can be 
done by measuring mRNA expression using different probe sets targeting the presence or absence of the two 
NLGN1 inserts48–50. Two days of Aβo1-42 injections significantly increased the hippocampal expression of ampli-
cons Nlgn1NA (p < 0.04) and Nlgn1C (p < 0.02) in comparison to control injections (Fig. 4B,E); whereas 4 days 
Figure 3. Aβo1-42 exposure impacts cell viability and NLGN1 in primary neuronal culture. (A) Neuronal 
viability of hippocampal neurons exposed to 2 µM of Aβo1-42 or vehicle (VH) for 48 and 72 hours. A significant 
Treatment-by-Time interaction was found (two-way ANOVA F1,39 = 12.6, p = 0.001), with difference between 
Aβo1-42 and VH restricted to 72 hours of treatment (stars indicating planned comparison, also in B). (B) NLGN1 
protein level in primary culture of hippocampal neurons was assessed by Western blot (top) and expressed 
relative to the control protein GAPDH (bottom) after exposure to 2 µM of Aβo1-42 or VH for 48 and 72 hours. 
A significant Treatment-by-Time interaction was also found (two-way ANOVA F1,22 = 5.43, p = 0.03), with 
difference between Aβo1-42 and VH also restricted to 72 hours of treatment. Full length blots are shown in 
Supplementary Fig. 4. The number of replicate is indicated on each bar.
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of injections significantly decreased the expression of amplicons Nlgn1NA (p < 0.04), Nlgn1NB (p < 0.05) and 
Nlgn1C (p < 0.01) (Fig. 4B,D,E). The Nlgn1A and Nlgn1B amplicons were not significantly changed by Aβo1-42 
injections (Fig. 4A,C). Also, hippocampal Aβo1-42 injections did not significantly affect the gene expression of the 
related synaptic proteins NLGN2, NRXN1, NRXN2 and NRXN3 (Supplementary Fig. 5). NLGN1 protein level, 
which was measured in the hippocampus of the other hemisphere, showed a tendency to be decreased by 4 days 
of Aβo1-42 injections similar to specific Nlgn1 amplicons (Fig. 4F, Supplementary Fig. 6), but the change did not 
reach statistical significance (p < 0.2). These results suggest a transcript variant-specific impact of Aβo1-42 on the 
expression of Nlgn1, and that this impact shows a bi-phasic time course with an initial increase followed by a 
decrease.
NLGN1 deletion worsens spatial learning deficits after treatment with Aβo1-42. We next tested 
the functional role of NLGN1 specifically in Aβo-induced in vivo damage. We first investigated the implication 
of NLGN1 specifically in Aβo-driven memory impairment using assessments of spatial and working memory, 
selected for their dependency on the hippocampus58,59. This was done using Nlgn1 KO mice and WT littermates 
submitted solely to 4 days of injections of Aβo1-42 or AβScr (Supplementary Fig. 1). The condition with 4 injection 
days was selected given that it specifically decreased expression of precise Nlgn1 transcripts (Fig. 4) and to obtain 
Figure 4. Chronic hippocampal injections of Aβo1-42 change Nlgn1 mRNA expression. Nlgn1 mRNA and 
protein expression was measured after 2, 4 or 6 days of hippocampal injections of Aβo1-42 or vehicle (VH). (A) 
Nlgn1A expression showed no change with treatment throughout the 6 days (two-way ANOVA Treatment 
main effect: F1,30 = 0.0009, p = 0.98; Treatment-by-Day interaction: F2,30 = 1.6, p = 0.2). (B) Nlgn1NA expression 
showed a significant Treatment-by-Day interaction (two-way ANOVA F2,29 = 4.77, p = 0.02) with significant 
difference between Aβo1-42 and VH after 2 and 4 days (stars indicating planned comparison, also in D and E). 
(C) Nlgn1B expression showed no change with treatment throughout the 6 days (two-way ANOVA Treatment 
main effect: F1,30 = 0.2, p = 0.6; Treatment-by-Day interaction: F2,30 = 0.2, p = 0.8). (D) Nlgn1NB expression 
showed a significant Treatment-by-Day interaction (two-way ANOVA F2,28 = 3.4, p < 0.05) with significant 
difference between Aβo1-42 and VH after 4 days. (E) Nlgn1C expression showed a significant Treatment-by-Day 
interaction (two-way ANOVA F2,28 = 8.0, p = 0.002) with significant difference between Aβo1-42 and VH after 2 
and 4 days. (F) Hippocampal NLGN1 protein level and loading control GAPDH measured by Western blot after 
chronic injections (top) and the quantification (bottom). No change was found with treatment throughout the 6 
days (two-way ANOVA Treatment main effect: F1,28 = 0.001, p = 0.9; Treatment-by-Day interaction: F2,28 = 0.22, 
p = 0.8). Full length blots are shown in Supplementary Fig. 6. The number of mice is 5–6 per group.
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an exposure to Aβo1-42 intermediate in comparisons to 6 days that was shown to induce substantial neuronal loss 
and memory deficits12.
First, SOR was differentially affected by Aβo1-42 in Nlgn1 KO and WT mice. Indeed, the number of interac-
tions with the moved object was significantly higher than the number of interactions with the fixed objects for 
Figure 5. NLGN1 absence impairs spatial memory after Aβo1-42 exposure. (A) Number of interactions with 
the fixed and moved objects in the SOR task for WT and Nlgn1 KO mice treated with Aβo1-42 or AβScr. Stars 
indicate significant differences between moved and fixed objects (t ≥ 2.6). (B) A Genotype-by-Treatment 
interaction was found for the discrimination index (DI) in the SOR task (two-way ANOVA F1,34 = 4.5, p = 0.04; 
stars indicate planned comparisons, also in E, F and J). (C) Percent time in the new and other arms in the 
Y-maze task for the four groups. Stars indicate significant differences between new and other arms (t ≥ 2.9). 
(D) Latency to the platform during the MWM training days showed significant effects of Genotype (three-way 
ANOVA F1,159 = 5.4, p = 0.02) and Day (F3,151 = 25,2, p < 0.0001) but no significant Genotype-by-Treatment-
by-Day interaction (F3,159 = 0.4, p = 0.7). (E) Latency to the platform during the MWM training trials showed 
significant Treatment-by-Trial (three-way ANOVA F3,151 = 2.9, p = 0.03) and Genotype-by-Treatment 
(F1,155 = 3.9, p < 0.05) interactions. (F) Graph of panel E Genotype-by-Treatment interaction showing the 
mean latency of all 12 trials. (G) Swimming speed during the MWM probe phase (two-way ANOVA Treatment 
F1,35 = 0.06, p = 0.8; Genotype F1,35 = 1.8 p = 0.2; interaction F1,35 = 0.03, p = 0.9). (H) Number of platform 
crossing during the MWM probe phase showed a significant Treatment effect (two-way ANOVA F1,39 = 6.2 
p = 0.02). (I) Percent time in the target and other quadrants during the MWM probe test showed a significant 
Treatment-by-Quadrant interaction (three-way ANOVA F1,77 = 8.6, p = 0.0045). (J) Percent time in the target 
quadrant showed for Aβo1-42 and AβScr injected animals. The number of mice is 9-10 per group.
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WT mice injected with AβScr (p = 0.004), WT mice injected with Aβo1-42 (p = 0.01) and KO mice injected with 
AβScr (p = 0.02), indicating memory for spatial location (Fig. 5A). However, Nlgn1 KO mice injected with Aβo1-42 
did not differ in the number of interactions between the moved and fixed objects (p = 0.6), suggesting impaired 
spatial memory (Fig. 5A). This is also reflected in the DI, which was significantly lower in KO mice injected with 
Aβo1-42 than in all other groups (p = 0.002 vs. Nlgn1 KO mice with control injections; p = 0.001 vs. WT mice with 
control injections; p = 0.002 vs. WT mice with Aβo1-42 injections; Fig. 5B). These results indicate that only animals 
lacking NLGN1 express SOR memory deficits with intermediate exposure to Aβo1-42. In contrast, working mem-
ory in the Y-maze did not significantly differ between Nlgn1 KO and WT mice both under control and Aβo1-42 
injections (Fig. 5C). All four groups indeed spent more time exploring the new arm in comparison to the other 
arms (p ≤ 0.001), which indicates preservation of working memory independent of the presence of NLGN1. The 
total distance traveled during the Y-maze test was equivalent between groups, whereas KO mice showed a small, 
but significant, decreased in the distance traveled during the SOR test (Supplementary Fig. 7).
Spatial memory was further tested in the MWM. As expected for the learning phase, the latency to reach the 
platform progressively decreased over training days (Fig. 5D). This decrease did not significantly differ between 
Nlgn1 KO and WT mice with Aβo1-42 and control injections, but the latency was globally higher in KO mice in 
comparison to WT mice (p = 0.02). When all trials of the 4 training days are considered separately (Fig. 5E), 
Aβo1-42 injected WT and KO mice showed a longer latency to reach the platform compared to AβScr injected 
WT and KO mice on the first trial of day 3 (p < 0.01). The first trial of each day was proposed to reflect memory 
retention57, for which deficits could be induced by Aβo1-42 independent of the genotype. Most importantly, Nlgn1 
KO mice injected with Aβo1-42 showed a significant overall higher latency to the platform than all other groups 
(p < 0.01 vs. Nlgn1 KO mice with control injections; p < 0.01 vs. WT mice with control injections; p < 0.001 vs. 
WT mice with Aβo1-42 injections), which is also illustrated in Fig. 5F. These findings are reminiscent of observa-
tions in the SOR task and further support a greater impact of Aβo1-42 on spatial learning in the absence of NLGN1.
In the MWM probe phase, the platform is removed, and the number of times mice are crossing the zone 
where it was and the time spent in the quadrant where it was located (target quadrant) are indicative of spatial 
memory. Beforehand, we verified that the swimming speed did not significantly differ between WT and KO 
mice with Aβo1-42 and control injections (Fig. 5G). This confirmed equivalent locomotion across genotypes and 
treatments, and excluded this potential confounding in the evaluation of memory. We found that Aβo1-42 signifi-
cantly reduced the number of platform crossing in the probe test independent of the genotype (p = 0.02; Fig. 5H). 
Similarly, Aβo1-42 injected animals spent a lower percentage of time in the target quadrant compared to AβScr 
injected animals (p < 0.01; Fig. 5I,J). Indeed, Aβo1-42 injected WT and KO mice were not different from the 25% 
time spent in quadrant, which represents chance, while AβScr injected mice clearly spent more than 25% time in 
the target quadrant (Fig. 5J). Taken together, results from the MWM suggest that the absence of NLGN1 worsens 
the impact of Aβo1-42 on learning, but not on the final acquired memory.
NLGN1 deletion reveals neuronal loss after treatment with Aβo1-42. Lastly, we asked whether the 
absence of NLGN1 impacts neuronal loss in the DG caused by chronic hippocampal Aβo1-42 injections. This was 
assessed using the same mice as above tested for spatial and working memory. Neuronal loss was measured in the 
DG in an area located under the injection site (Fig. 6). The size of the counting area did not differ between groups 
(Fig. 6C). However, DG neuronal count was significantly decreased in Nlgn1 KO mice submitted to Aβo1-42 injec-
tions in comparison to all other groups (p = 0.02 vs. Nlgn1 KO mice with control injections; p = 0.02 vs. WT mice 
with control injections; p = 0.002 vs. WT mice with Aβo1-42 injections; Fig. 6D). Of note is that WT mice injected 
with Aβo1-42 did not significantly differ from WT mice with control injections, thus confirming an intermedi-
ate (sub-clinical) exposure to Aβo1-42. Neuronal count in a region distant to the injection site (i.e., CA2-CA3) 
revealed no significant difference between the four groups (Supplementary Fig. 8). These results suggest that the 
absence of NLGN1 potentiates the toxicity of Aβo1-42, leading to a noticeable neuronal loss in the DG.
Discussion
Our findings provide insight on the involvement of NLGN1 in neurodegeneration. We first report that NLGN1 
protein is decreased in the hippocampus of aMCI individuals and AD patients, in whom its level correlates with 
soluble Aβ and cognitive function. We then found that NLGN1 protein is also decreased, at an early develop-
mental age, in the hippocampus of a mouse model showing Aβ pathology. Further, we revealed that the specific 
exposure to Aβo1-42 decreases NLGN1 protein in hippocampal neurons in culture and modulates Nlgn1 hip-
pocampal expression in a transcript variant-dependent manner. Importantly, we demonstrated a negative effect 
of the absence of NLGN1 on Aβo1-42 toxicity, with Nlgn1 KO mice showing neuronal loss and greater deficits in 
spatial learning when injected with Aβo1-42 in comparison to WT animals. These results are supporting an impact 
of Aβo1-42 on NLGN1 as well as a modulatory role for NLGN1 in the toxicity induced by Aβo1-42.
To our knowledge, our study is the first to show that NLGN1 level in the hippocampus is decreased in aMCI 
individuals and AD patients. This result is in line with the recent report that NLGN1 is decreased in the plasma 
of AD patients and in individuals with less severe cognitive symptoms39, and may suggest that changes in the hip-
pocampus could contribute to plasmatic changes. It also aligns with our previous findings of decreased synaptic 
proteins linked to glutamatergic transmission (e.g., PSD95, GluN2B) in the hippocampus of aMCI patients53. Our 
observation that the NLGN1 decrease is of greater magnitude than the PSD95 decrease emphasizes the particular 
relevance of considering the role of NLGN1 in neurodegeneration. Such a role is also supported by the observa-
tion of a NLGN1 mutation affecting its function in a patient with AD35. Moreover, the finding that NLGN1 level 
in the aMCI/AD hippocampus correlates with cognitive function supports the idea that synaptic dysfunction 
adequately predicts cognitive decline in AD1–3,22. Even if the exact mechanisms underlying NLGN modification 
in aMCI and AD remains to be identified, plasmatic NLGN1 or even hippocampal NLGN1 measured via imaging 
may be considered as an early biomarker of AD.
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Importantly, we observed that the decrease in hippocampal NLGN1 protein is also an early event occurring 
in a recognized mouse model of AD (i.e., 3xTg-AD). Indeed, decreased NLGN1 was found at 4 months, an 
age at which cognitive symptoms are just starting to manifest and have been attributed to intraneuronal Aβ57. 
This model generally shows signs of neuronal death, human Aβ precursor protein (hAPP) deregulation, and 
Tau pathology later in life42,60,61, but these may all contribute to NLGN1 decrease together with alterations in 
Preselinin-1 in this model. The observation that only the females show this early decrease likely resides in the 
worst pathology observed in 3xTg-AD females in comparison to 3xTg-AD males. Indeed, 3xTg-AD females 
have repeatedly been reported to have, in particular, higher hAPP and Aβ levels than males60,62,63. Alternatively, a 
compensatory mechanism linked to the encoding of other NLGNs by sex chromosomes64,65, could also contribute 
to the sex-dependent decrease in NLGN1. Of interest is also that we found a genotype-independent decrease in 
NLGN1 level with age in male mice (also significant when females and males are pooled). This age-dependent 
decrease in hippocampal NLGN1 could definitely contribute to the main risk factor for neurodegeneration, 
namely age. More precisely, a progressive decrease in NLGN1 in the hippocampus may increase the susceptibility 
of this key brain region to synaptic and cell loss, such as under exposure to Aβo.
Our discovery that NLGN1 level in the hippocampus of aMCI individuals and AD patients significantly cor-
relates with soluble Aβ could suggest a specific contribution of the Aβ pathology in decreasing NLGN1 level. We 
indeed specifically found that exposure to Aβo1-42 reduces NLGN1 level in cultured hippocampal neurons, similar 
to a recent study66. From these data, we cannot exclude a direct effect of neuronal death on NLGN1 level because 
the NLGN1 decrease paralleled the neuronal viability decrease. Still, these findings are revealing a synaptic com-
ponent linked to the established neurotoxicity of Aβo as well as their correlation with cognitive functioning in 
AD patients and animal models9–18, given the roles of NLGN1 in cognition and its cellular correlates3,31–33,64. Of 
note is that Aβ1-40 fibrils, which are generally considered less neurotoxic than Aβo11,19, have also been shown to 
negatively impact NLGN1 protein level in the rat hippocampus36. The precise manner by which Aβo are decreas-
ing the level of NLGN1, as well as the contribution of neuronal death, remains a question of particular relevance 
to evaluate the potential for NLGN1 to become a therapeutic target. Previous reports have indicated that Aβo are 
directly interacting with NLGN1 in vitro37,38. Such a direct interaction may contribute to an increased NLGN1 
protein degradation. Alternatively, the Aβo-induced NLGN1 decrease could result from changes in Nlgn1 gene 
expression linked to epigenetic modifications such as what has been observed for Aβ fibrils36.
An impact of Aβo on Nlgn1 gene expression is indeed supported by our findings in chronic hippocampal 
injections. Importantly, the different durations of Aβo treatment we have used allowed for the observation of a 
bi-phasic time course comprising an initial increase followed by a decrease. Moreover, this expression pattern 
was found only for specific Nlgn1 variants and not for other variants or other related genes (i.e, Nlgn2, Nrxns). 
In fact, the initial increase was observed for Nlgn1 without insert in splice site A, and the following decrease for 
Nlgn1 without insert in sites A and B. These changes were substantial enough to be also captured by the common 
probe, but strongly suggest that the expression of Nlgn1 without insert is primarily affected by Aβo. In contrast 
with other isoforms, the isoform of NLGN1 not containing any insert is located equally at glutamatergic and 
Figure 6. NLGN1 absence induces neuronal loss after Aβo1-42 exposure. (A) Representative IF images of NeuN 
staining (green) in the full hippocampus. The approximate location of the counting area is indicated by the 
yellow rectangle. Magnification 2.5X. (B) Representative IF images of NeuN staining (green) in the DG, where 
neuron counting was conducted. One image per group is showing approximately the same position within the 
DG. Magnification 40X. (C) Quantification of the area covered by the counting zone, which did not significantly 
differ between groups (two-way ANOVA Genotype main effect: F1,20 = 0.6, p = 0.4; Treatment main effect: 
F1,20 = 0.1 p = 0.8; Genotype-by-Treatment interaction: F1,20 = 0.2, p = 0.7). (D) Number of NeuN-marked cells 
counted in the DG target area showed a significant Genotype-by-Treatment interaction (two-way ANOVA 
F1,20 = 8.1, p = 0.01), with the KO Aβ group showing a significant difference in the number of immunoreactive 
cells in comparison to all other groups (star indicates planned comparisons). The number of mice is 6 per group.
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gamma-aminobutyric acid (GABA) synapses67. This could suggest that the negative impact on NLGN1 could 
play a role in GABAergic synapse dysfunctions observed in AD and animal models68,69, as well as in glutamatergic 
synapse modifications8,12,21. Besides, the initial increase in Nlgn1 expression after 2 days of Aβo exposure might 
belong to a neuroprotective pathway similar to other pathways driven by Aβ in the hippocampus70. NLGN1 was 
already shown to protect against oxidative stress in a non-mammalian model71 and to express neuroprotective 
functions in hippocampal neurons38,72. Alternatively, lower Nlgn1 expression at 4 days of Aβo exposure may 
result from an increased expression with the vehicle injection, which could also be linked to a neuroprotec-
tive role of NLGN1 in response simply to intra-hippocampal injections. This effect would again be very spe-
cific to Nlgn1 lacking any insert and would be counteracted by Aβo exposure. The fact that a modulation by 
chronic Aβo hippocampal injections could not be detected at the protein level likely results from the absence of 
an isoform-specific antibody. Indeed, a change in NLGN1 isoform without insert could be masked by the absence 
of change in NLGN1 with insert B, which transcript is highly expressed in the hippocampus67.
In the second part of our study, we provide data supporting a modulatory role of NLGN1 on spatial learning 
deficit and neuronal loss mediated by exposure of the hippocampus to Aβo1-42. Firstly, Nlgn1 KO mice injected 
with Aβo1-42 were the only group showing memory impairment in SOR. A similar finding was made in the MWM 
training phase, during which Nlgn1 KO mice injected with Aβo1-42 showed a longer overall latency to reach the 
platform. Deficits have been observed in KO mice with a lower exposure/dose than those generally inducing 
impairments in SOR and the MWM task in WT animals52,73,74. Nlgn1 KO mice were previously shown to have 
only a very subtle deficit in the MWM and to have a preserved locomotion33, which are in line with our observa-
tions of very few deficits in vehicle-injected KO mice. The fact that KO mice injected with Aβo1-42 were impaired 
specifically in the MWM training phase, whereas Nlgn1 KO mice are not33, also emphasizes a more specific impli-
cation of NLGN1 in modulating Aβo-induced deficits in learning or in memory acquisition. Of note is that this 
effect of NLGN1 seems restricted to spatial memory given that working memory assessed using the Y-maze was 
not affected by chronic hippocampal injections of Aβo. Although a longer exposure of the hippocampus to Aβo 
was shown to impair memory using a similar task12, the lack of effect in the current study is likely resulting from 
working memory involving to a great extent the cerebral cortex75,76. The manner by which NLGN1 modulates 
spatial learning deficits mediated by Aβo will need to be determined in future studies. Yet, the literature could 
point to mechanisms related to direct physical interactions between NLGN1 and Aβo37,38 potentially sequestering 
toxic oligomers, or linked to NLGN1 cleavage that occurs in response to sustained synaptic activity72.
Secondly, neuronal count in the DG was decreased only in Nlgn1 KO mice. The absence of NLGN1 thus seems 
to increase the neurotoxicity of Aβo by inducing neuronal loss following an intermediate exposure (i.e., 4 days) 
whereas neuronal loss is generally obtained from longer exposure (i.e., 6 days) or higher doses12,73,74, similar to 
memory deficits. It should be noted, however, that the NeuN staining used here is not a direct indication of neu-
ronal death, but that other accepted markers of neurodegeneration such as Caspase-3 and Fluoro-Jade B12,77 could 
not be used in the present study due to the sacrifice of animals being performed multiple days after exposure to 
allow for the evaluation of memory. Nevertheless, our finding supporting that NLGN1 can oppose Aβo-driven 
neurotoxicity in the DG is in line with observations that a soluble fragment of NLGN1 diminishes the negative 
impact of Aβo on excitatory synaptic transmission in hippocampal slices38 and that NLGN1 is part of a pathway 
counteracting Aβo-induced synaptotoxicity in cultured hippocampal neurons66.
Conclusions
We here reveal that NLGN1 is decreased in the hippocampus of patients with prodromal signs of and estab-
lished neurodegeneration in a symptomatology-dependent manner and, using in vitro and in vivo models, that 
this change is likely driven, at least in part, by Aβo and contributing to cognitive decline. In parallel, our data 
expose a bi-directional relationship between NLGN1 and Aβo, in which the accumulation of Aβo1-42 negatively 
impacts NLGN1, and decreased NLGN1 renders neurons/synapses more vulnerable to Aβo1-42 translating in 
memory deficits and neuronal loss. Our findings support a potential for strategies enhancing NLGN1 to alleviate 
symptoms of AD, which reconciles with previous research36,38,78, including with that reporting NRXN-NLGN 
mutations in AD patients34,35. On the contrary, our study does not support approaches opposing NLGN1 as a 
therapeutic strategy in AD such as the use of anti-NLGN1 antibody37. The current research provides additional 
insight in the development of early diagnostic tools and treatments of aMCI and AD, which is of crucial impor-
tance to benefit the quality of life of millions of AD patients worldwide.
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